**ABSTRACT**

**BACKGROUND**
The presence of *Plasmodium falciparum* resistance and decreased efficacy of artemisinin and its derivatives has resulted in the issue of malaria becoming increasingly complex, because there have been no new drugs as artemisinin replacements. The aims of this research were to evaluate in vitro changes in ultrastructural morphology of *P. falciparum* 2300 strain after exposure to artemisinin.

**METHODS**
The research used an experimental design with post test only control group. Cultures of *P. falciparum* 2300 strain in one control and one mutant group were treated by exposure to artemisinin at IC₅₀ 10⁻⁷ M for 48 hours. Ultrastructural phenotypic examination of ring, trophozoite and schizont morphology and developmental stage in the control and mutant group were done at 0, 12, 24, 36, 48 hours by making thin blood smears stained with 20% Giemsa for 20 minutes and examined using a microscope light at 1000x magnification.

**RESULTS**
Dormant forms occurred after 48 hours of incubation with IC₅₀ 10⁻⁷ M artemisinin in the control group. In the mutant group, dormant forms, trophozoites with blue cytoplasm and normal schizont developmental stages were seen. Ultrastructural phenotypic morphology at 0, 12, 24, 36, 48 hours showed that in the control group dormant formation already occurred with exposure to IC₅₀ 10⁻⁷ M, while in the mutant group dormant formation occurred only with exposure to IC₅₀ 2.5x10⁻⁵ M.

**CONCLUSION**
Exposure to artemisinin antimalarials in vitro can cause phenotypic morphological changes of dormancy in *P. falciparum* Papua 2300 strain.

**Keywords**: Artemisinin, *P. falciparum* 2300, phenotype, resistance
Induksi bentuk dorman Plasmodium falciparum galur 2300 oleh artemisinin

ABSTRAK

LATAR BELAKANG
Resistensi parasit P.falciparum dan penurunan efek artemisinin dan derivatnya menyebabkan masalah malaria menjadi semakin kompleks, karena belum ada obat baru pengganti artemisinin. Penelitian ini bertujuan untuk menilai efek paparan artemisinin terhadap morfologi ultrastruktur Plasmodium falciparum galur 2300.

METODE
Penelitian menggunakan experimental design dengan post test only control group. Kultur P. falciparum galur 2300 kelompok kontrol dan kelompok mutan diberikan perlakuan paparan artemisinin dengan dosis IC\textsubscript{50} $10^{-7}$ M selama 48 jam, kemudian dilakukan pengamatan gambaran ultrastruktur P.falciparum galur 2300. Pemeriksaan fenotip ultrastruktur stadium perkembangan dan morfologi ring, trofosoit dan skizon pada kelompok kontrol dan kelompok mutan dilakukan setiap 12 jam setelah dipapar artemisinin. Selanjutnya pada jam ke 0, 12, 24, 36, 48 dibuat hapusan darah tipis yang diwarnai dengan Giemsa 20 % selama 20 menit dan dilakukan pemeriksaan menggunakan mikroskop cahaya perbesaran 1000x.

HASIL
Bentuk dorman terjadi setelah 48 jam diinkubasi artemisinin dosis IC\textsubscript{50} $10^{-7}$ M pada P. falciparum 2300 kelompok kontrol sedangkan pada kelompok mutan P. falciparum 2300 gambaran ultrastruktur terdapat stadium perkembangan bentuk dorman, trofosoit dengan sitoplama berwarna biru dan skizon normal. Gambaran fenotip ultrastruktur pada kelompok kontrol dan kelompok mutan pada jam ke 0, 12, 24, 36, 48 menunjukkan pada kelompok kontrol dengan paparan dosis IC\textsubscript{50} $2.5 \times 10^{-5}$ M sudah terjadi bentukan dorman sedangkan pada kelompok mutan dengan paparan dosis IC\textsubscript{50} $2.5 \times 10^{-5}$ M baru terjadi bentuk dorman.

KESIMPULAN
Bentuk dorman terjadi di kelompok mutan hanya dengan peningkatan dosis paparan artemisinin.

Kata kunci : Artemisinin, fenotip, P. falciparum galur 2300, resistensi

INTRODUCTION

Malaria is one of the infectious diseases with a global distribution, ranging from the tropics, subtropics to temperate climates. Malaria is still a public health problem in more than 90 countries that are inhabited by 2.4 billion people or 40% of the world population. In 2008, the World Health Organization (WHO) estimated that there were approximately 243 million cases of malaria and 886,000 deaths because of malaria, most of them in sub-Saharan Africa due to falciparum malaria in children under the age of five years. In addition to its impact on health, malaria imposes a heavy economic burden on individuals and entire economies.

Prevention efforts against malaria have been carried out, but the morbidity and mortality rates of malaria in some countries are still high. Among the factors that cause difficulties in malaria prevention, Plasmodium resistance to antimalarial medications is the factor which is...
most difficult to overcome because of the occurrence of mutations in the genome of
Plasmodium that are difficult to control.\(^{1}\)

The most recent and currently used drugs for malaria therapy are artemisinin and its
derivatives, but there have been indications that the Plasmodium parasites are now resistant to
these drugs.\(^{4}\) A clinical study found two patients in Cambodia who had been infected with
Plasmodium falciparum (P. falciparum) to be resistant to artesunate.\(^{5}\) Because of that, the
eradication of malaria has become more complex and dangerous. It is one of the world health
problems that have to date not yet been resolved because of the absence of artemisinin substitutes.
The development of Plasmodium resistance to antimalarial drugs which occurs faster than the
development of new antimalarials becomes a consideration for seeking solutions to the accurate
and efficient therapeutic management of malaria.

Resistance of P. falciparum to artemisin
may be influenced by internal factors of P. falciparum, due to changes in the parasite itself
to allow it to survive and adapt to environmental changes caused by drug exposure. The results
of studies have pointed to the deceleration of the developmental life cycle and the induction of the
expression of genes that code for proteins (protein overexpression) as one of the important
mechanisms for the Plasmodium parasite to free themselves from the effects of antimalarial
medication and still be able to survive.\(^{6}\) Another research study was conducted by molecular
monitoring of the genes that are involved in P. falciparum resistance to antimalarials.\(^{7,8}\) The
research results found that combined artemisinin resistance may be due to mutations in the P. falciparum
adenine triphosphatase 6 (pfatpase6) gene.\(^{7}\)

Although the mechanism of artemisinin resistance is unclear, it is suspected that there are changes in antimalarial resistance at phenotypic, proteomics, and genotypic levels in
Plasmodium. At the genotypic level, one of the changes are due to a mutation in the pfatpase6
gene and upregulation of expression of gene transcription.\(^{9}\) The relationship of repeated
artemisinin exposure with phenotypic, proteomics and genotypic changes in chloroquine
resistant P. falciparum has not been proved, necessitating the present study.

Previous research on the P. falciparum F32-Tanzania strain that was exposed for 3 years to
artemisinin at low concentrations ranging from 0.01 \(\mu\)M up to 10 \(\mu\)M for 100 exposure times.
Drug-selected F32-ART parasites were the result of treatment with high doses of artemisinin
(ART) for 48 h to 96 h, after which the parasites were returned to normal culture without the drug
for 21 days until parasitemia reached 5%. The drug-selected parasite F32-ART could recover
from ART treatment in a much shorter time than the F32-Tanzania did and survive.\(^{10}\) Another
research showed that P. falciparum strains GC06 and CH3-61 before and after selection with
artemisinin at increasing concentrations from 0 to 20 nM and 0 to 100 nM, respectively, the IC\(_{50}\) value of the selected and viable GC06 parasites increased.\(^{11}\) This study was conducted to
evaluate the effect of in vitro artemisinin exposure at IC\(_{50}\) doses on the morphological changes in P. falciparum 2300 mutant strain.

**METHODS**

**Research design**

The research used an experimental design with post test only with control group. Cultures of P. falciparum 2300 mutant strain were used in the control group and mutants. Parasitemia and morphological examinations were conducted at the Faculty of Veterinary Medicine, Airlangga University, from March to October 2013.

**Research sample**

The samples that were used as controls in this study were cultures of P. falciparum 2300 mutant strain that had become resistant to chloroquine, whereas for the mutant cultures of P. falciparum 2300 mutant strain were used that had become resistant to both chloroquine and artemisinin.
Experimental design
The Plasmodium cultures were divided into two treatment groups, i.e. the control group and the mutant. The control group was exposed to artemisinin in vitro at a concentration equivalent to IC$_{50}$ 10$^{-7}$ M, whereas the mutant was exposed to artemisinin at a dose of IC$_{50}$ 2.5x10$^{-5}$ M, both groups being exposed for 48 hours. Ultrastructural phenotypic examination of ring, trophozoite and schizont morphology and developmental stages were observed in both groups at 0, 12, 24, 36, 48 hours.

Culture and morphological examination
Cultures of P. falciparum 2300 mutant strain that had been stored in liquid nitrogen were thawed by the Rowe method. One millimeter of the erythrocyte suspension was taken and mixed with 9 ml of complete medium plus 15% human serum type O, then put into a culture flask and incubated in a CO$_2$ incubator at 37ºC, under 5% CO$_2$, 5% O$_2$ and 90% N$_2$. Medium replacement was done carefully every 48 hours using a sterile Pasteur pipette. A sample of the sediment was taken to make a smear to determine parasitemia, then 9 mL of medium was added to each culture flask and the culture was incubated again.

Phenotypic observations of the morphology and developmental stages of the intra-erythrocytic cycle of P. falciparum 2300 strain were carried out on synchronized and non-synchronized cultures that had been incubated for 48 hours. Plasmodium cultures were divided into two treatment groups, i.e. the control group and mutant group with artemisinin exposure in vitro at IC$_{50}$ 10$^{-7}$ M concentration and 48 hours of incubation.

As seen in Figure 2, the morphology of P. falciparum 2300 strain were different in the control group as compared with the mutant group, before and after treatment with artemisinin at IC$_{50}$ 10$^{-7}$ M concentration and 48 hours of incubation. From Figures 3 and 4 it is also apparent that the developmental morphologies of P. falciparum of the synchronized control and mutant 2300 strains after exposure to artemisinin at IC$_{50}$ concentrations and 12-hourly observation, were different from each other.

DISCUSSION
The results of the study showed that in the control group that was exposed to artemisinin at 10$^{-7}$ M concentration and incubated for 48 hours, the growth percentage decreased to 35% and growth inhibition decreased to 65%. Morphological description showed that there were dormant forms. The mutant group that was exposed to artemisinin at 10$^{-7}$ M concentration and incubated for 48 hours had a growth
percentage of 92% and growth inhibition of 8%. Morphological description also showed dormant forms, trophozoites with cytoplasm that still appear blue and the presence of normal schizonts containing merozoites with brownish black pigment (Figures 1 and 2). The results of this study showed that the parent \textit{P. falciparum} 2300 strain requires smaller artemisinin concentrations to show growth inhibition compared to the mutant \textit{P. falciparum} 2300 strain that had become resistant to artemisinin, which required greater artemisinin concentrations to show growth inhibition of the parasites. It can already be seen from the morphological description that at the same artemisinin concentration (10^{-7} \text{M}), there are morphological changes in the mutant group when compared to the control group. In the mutant group, there are morphological changes in their ring, schizont and trophozoite developmental stages, which are normal. Therefore, from the morphological description it can be concluded that to obtain the same dormant period a greater concentration of artemisinin is required.

The results of this study also showed that the dormant period can occur in parasite strains that are resistant to artemisinin, but it needs a higher drug concentration for its induction. \textit{Plasmodium} parasites that are resistant to artemisinin cannot be induced into a dormant period if there had been tolerance to the drug concentration. It is possible that the dormant period

![Figure 1. Percentage growth inhibition of \textit{P. falciparum} 2300 strains in control and mutants exposed to artemisinin](image)

Figure 2. Parent and mutant \textit{P. falciparum} morphology after being exposed for 48 hours to artemisinin at IC_{50} dose (1000x magnification). Giemsa staining. Arrow color codes: black = dormant, red = ring, yellow = trophozoite, green = schizont, blue = merozoite. (A) Parent \textit{P. falciparum} 2300 strain, (B) Parent \textit{P. falciparum} 2300 strain after being exposed to artemisinin 10^{-7} \text{M} for 48 hours, (C) Mutant \textit{P. falciparum} 2300 strain, (D) Mutant \textit{P. falciparum} 2300 strain after being exposed to artemisinin10^{-7} \text{M} for 48 hours
Figure 3. Morphology of *P. falciparum* 2300 strain synchronized in the control group, treated with artemisinin at IC$_{50}$ 10$^{-7}$ M concentration, and monitored every 12 hours (1000x magnification). Giemsa staining. Black arrow = dormant, red = ring, yellow = trophozoite, green = schizont, blue = merozoite.
Figure 4. Morphology of *P. falciparum* 2300 strain synchronized in the viable mutant group, treated with artemisinin at IC₅₀ 2.5x10⁻⁵ M concentration, and monitored every 12 hours (1000x magnification). Giemsa staining. Black arrow = dormant, red = ring, yellow = trophozoite, green = schizont, blue = merozoite.
parasites use innate mechanisms to survive the stressor, i.e. the drug concentration that can cause severe damage to the parasite, and that the dormant parasites can also be triggered when parasite growth is inhibited.(13,14)

The results of this research are in agreement with those of research conducted on *P. falciparum* GC06 and CH3-61 strains before and after selection with artemisinin at increasing concentrations of 0 to 20 nM and 0 to 100 nM, respectively, where viable parasites showed an increase in IC$_{50}$ strain values after selection with artemisinin. IC$_{50}$ strain values increased in the first GC06 strain from 3.1 ± 0.1 nM to 12.5 ± 1.6 nM and in the first CH3-61 strains that from 28.8 ± 1.3 nM to 58.3 ± 4.5 nM.(11) The results of research on *P. falciparum* Tanzania F32 exposed to artemisinin for 3 years at low concentrations ranging from 0.01 µm up to 10 µm for 100 exposure times, resulting in the selection of F32-ART strains, showed that at higher concentrations of artemisinin exposure (35 µm and 70 µm) for 96 hours, only the F32-ART strain was able to survive.(10)

Stage of development and morphology of the intra-erythrocytic cycle of *P. falciparum* 2300 strain that was synchronized in the control group, treated by artemisinin exposure at IC$_{50}$ concentration and observed every 12 hours, from 0 to 48 hours showed normal morphology development with faster growth compared with the group treated with artemisinin exposure at IC$_{50}$ concentration. The treatment group that was exposed to artemisinin showed dormant morphology development with nuclear chromatin condensation and if able to survive exposure to artemisinin, it only survives up to 24 hours after exposure, with imperfect ring and trophozoite stages.

The results of this study showed that cell cycle development in the control group proceeds normally while *P. falciparum* in the mutant group that was not exposed to artemisinin had a faster intra-erythrocytic life cycle. The increased growth of *P. falciparum* that had been exposed to artemisinin is caused by upregulation of gene transcription (multi-gene) that plays a role in cell cycle regulation, transport of substances from erythrocytes into the parasite, the enzymes involved in the biosynthesis of purines in DNA synthesis and synthesis of proteins that play a role in the adaptation of parasites to the environment in the early stage of parasite growth (16-20 hours) during the development of the ring forms into trophozoites and at the end of development (36-40 hours) when trophozoites develop into schizonts.(10,15)

In the group that was treated with artemisinin exposure at IC$_{50}$ concentration, there was decreased intra-erythrocytic development of *P. falcifarum*. The results of this study are comparable to those of research by Veiga et al.(16) who performed mefloquine exposure on three strains of Plasmodium (W2, 3D7 and FCB). Compared with the control treatment, 40% of cell morphology showed retarded development. Exposure to anti-malarial medications caused a 1.5-fold increase in *pfmdr1*, *pfcrt*, *pfmrp1* and *pfmrp2* gene expression. Similarly, upon quinine exposure for 12 hours, there was a slowdown in the development of cell morphology. The results of this research demonstrate that a slowdown in the development of *P. falciparum* is a very important mechanism for the parasite to be able to escape from the influence of anti-malarial medications.(6,16)

Morphological dormancy in *P. falciparum* that have been exposed to artemisinin is a defense mechanism for the parasites to be able to survive from the exposure of artemisinin anti-malarial medication. The parasites will be able to grow normally after the pressure from the drug is removed. In this dormant period, parasites can survive in a few days by slowing down the process of metabolism to limit the effects of the medication, because in this dormant period there is no DNA synthesis.(10,17-19)

Parasites that survive in the trophozoite stage from exposure to artemisinin have abnormal morphology, with formation of condensed cytoplasm. In *P. falciparum* that have been exposed to artemisinin for 48 hours,
morphological changes occur from the trophozoite stage until the final phase of the life cycle. Artemisinin exposure causes metabolic changes in the parasites that affect its growth and development, as can be observed from the morphological abnormalities. The changes start to occur at the trophozoite stage because at this stage, the parasites begin a process of active metabolism, growing larger in size from initial trophozoites into mature trophozoites. The nutrients extracted from the erythrocyte cytosol will be consumed quickly in the digestive vacuole that has started to form. The hemoglobin degradation process into oligopeptides and heme by proteolysis in the digestive vacuole is initiated to fulfill the nutritional needs of the parasite.\(^{20,21}\)

Abnormal morphology and growth inhibition after artemisinin exposure is also caused by the inhibition of parasite proteases (plasmepsin, falcipain and falcilysin) which are essential for parasite growth. Research by Bonilla et al.\(^{22}\) showed that \textit{Plasmodium} knockout mutants (triple and quadruple Plasmepsins Knockout Mutants, PMKO) in the protease enzyme have a deficiency in the endosomal vesicles that enter the digestive vacuole and produce multilamellar bodies, causing a deficiency in hemoglobin digestion and inhibition of hemozoin formation in the digestive vacuole, thus slowing growth.

Barriers artemisinin in endocytosis causes an inhibition of transport vesicle fusion into the digestive vacuole, so that the digestion of hemoglobin does not occur or is blocked. The relationship between endocytic transport and cellular signal transduction pathways that lead to inhibition of endocytosis will slow the growth of the parasites and result in reduction of parasitemia and parasite mortality.\(^{23,24}\)

One limitation of this research is that it was conducted only with the \textit{P. falciparum} Papua 2300 strain. A better way would have been to use more than one strain, so that the results could be compared. The implication of this research is that it may explain the mechanism of the development of resistance to artemisinin through phenotypic dormancy of \textit{P. falciparum} which can cause a decrease in artemisinin efficacy and give rise to recrudescence and artemisinin treatment failure. Further research needs to be done to visualize the ultrastructural changes of digestive vacuoles and mitochondria of \textit{P. falciparum} by transmission electron microscopy (TEM) and to determine changes at proteomic and genomic level, then performing an in vivo research in experimental animals as models of artemisinin resistance in humans.

**CONCLUSION**

Exposure to artemisinin antimalarials in vitro can cause phenotypic morphological changes of dormancy in \textit{P. falciparum} Papua 2300 strain.

**ACKNOWLEDGMENTS**

We would like to thank the Directorate General of Higher Education (\textit{Dirjen Dikti}), Ministry of Education and Culture, Republic of Indonesia for BPPS doctoral program 2009 in Faculty of Medicine Airlangga University.

**REFERENCES**

1. World Health Organization. World Health Organization global report on antimalarial drug efficacy and drug resistance 2000-2010. Geneva: World Health Organization; 2010.
2. Chima RI, Goodman CA, Mills A. The economic impact of malaria in Africa: a critical review of the evidence. Health Policy 2003;63:17-36.
3. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002;415:680-5.
4. Afonso A, Hunt P, Cheesman S, et al. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes \textit{atp6} (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase) tctp, \textit{mdr1} and \textit{cg10}. Antimicrob Agents Chemother 2006;50:480-9.
5. Noedl H. Evidence of artemisinin resistant malaria in Western Cambodia. N Engl J Med 2008;359:2619-20.
6. Veiga MI, Ferreira PE, Schmidt BA, et al. Antimalarial exposure delays \textit{P. falciparum} intra
erythrocytic cycle and drives drug transporter genes expression. Plos One 2010;5:e12408.

7. Mugittu K, Genton B, Mshinda H, et al. Molecular monitoring of *Plasmodium falciparum* resistance to artemisinin in Tanzania. Malaria J 2007;6:2. doi: 10.1186/1475-2875-6-2.

8. Schonfeld M, Miranda IB, Schunk M, et al. Molecular surveillance of drug resistance associated mutation of *Plasmodium falciparum* in Southwest Tanzania. Malaria J 2007;6:2. doi: 10.1186/1475-2875-6-2.

9. Maslachah L. Efek paparan artemisinin berulang terhadap perkembangan *Plasmodium falciparum* resisten in vitro [disertasi]. Program Studi Ilmu Kedokteran Program Doktor. Surabaya: Fakultas Kedokteran Universitas Airlangga; 2013.

10. Witkowski B, Lelievre J, Barragan MJL, et al. Increased tolerance to artemisinin in *Plasmodium falciparum* is mediated by a quiescence mechanism. Antimicrob Agents Chemother 2010;54:1872-7. doi: 10.1128/AAC.01636-09.

11. Beez D, Sanchez CP, Stein WD, et al. Genetic predisposition favors the acquisition of stable artemisinin resistance in malaria parasites. Antimicrob Agents Chemother 2010;55:50-5. doi: 10.1128/ACC.00916-10.

12. Sanz LM, Crespo B, De-cozar C, et al. *P. falciparum* in vitro killing rates allow to discriminate between different antimalarial mode of action. Plos One 2012;7:e30949.

13. Teuscher F, Chen N, Kyle DE, et al. Phenotypic changes in artemisinin resistant *Plasmodium falciparum* line in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Antimicrob Agent Chemother 2012;56:428-31.

14. Cheng Q, Kyle DE, Gatton ML. Artemisinin resistance in *Plasmodium falciparum*: a process linked to dormancy. IJP 2012;2:249-55.

15. Babbit SE, Altenhofen L, Cobbold SA, et al. Plasmodium falciparum responds to amino acid starvation by entering into a hibernatory state. PNAS 2012;109:E3278-87.

16. Tucker MS, Mutka T, Gil M, et al. In vitro recrudescence of *Plasmodium falciparum* parasites suppressed todormant state by atovaquone aloneand in combination with proguanil. J Trop Med Hygiene 2005;99:62.

17. Phadke MS, Krynetskain NF, Mishra AK, et al. Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines. J Pharmacol Exp Ther 2009;331:77-86.

18. Tucker MS, Mutka T, Sparks K, et al. Phenotypic and genotypic analysis of in vitro selected artemisinin resistant progeny of *Plasmodium falciparum*. Antimicrob Agent Chemother 2012; 56:302-14.

19. LaCrue AN, Scheel M, Kennedy K, et al. Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model *Plasmodium vincke*. Plos One 2011;6:e26689.

20. Rosenthal PJ. Antimalaria chemotherapy mechanism of action resistance and new direction in drug discovery. J Antimicrob Chemother 2003;51:1053. doi: 10.1093/jac/dkg183

21. Cowman AF, Berry D, Baum J. The cellular and molecular basis for malaria parasite invasion of human red blood cell. JCB 2012;196:962-71.

22. Bonilla AJ, Bonilla DT, Yowell AC, et al. Critical roles for digestive vacuole plasmepsins of *Plasmodium falciparum* in vacuolar function. Molecular Microbiol 2007;65:64-75.

23. Klonis N, Ortiz MP, Bottova I, et al. Artemisinin activity against *Plasmodium falciparum* requires hemoglobin uptake and digestion. PNAS 2011;108:11405-10.

24. Vieira A. Endocytic transport and some of its implications for physiology, metabolism and disease. J Physiobiochem Metab 2012;1:2.